Safety and efficacy of bortezomib (VELCADE™) in 104 patients with relapsed and/or refractory multiple myeloma who have received at least two previous lines of therapy:: Impact of cytogenetics on response from a Canadian cohort.

被引：0
作者：
Mikhael, Joseph R.
Reece, Donna E.
Belch, Andrew
Bahlis, Nizar J.
Sharma, Deepa
机构：
[1] Univ Hlth Network, Princess Margaret Hosp, Toronto, ON, Canada
[2] Cross Canc Inst, Edmonton, AB, Canada
[3] Tom Baker Canc Clin, Div Hematol Malignancies, Calgary, AB, Canada
[4] Ortho Biotech, Med Affairs, Toronto, ON, Canada
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.5118.5118
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5118
引用
收藏
页码：369B / 369B
页数：1
相关论文
empty
未找到相关数据